Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma -

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma
Information type: Other primary research
Source: The Lancet Oncology
Specialities: Cancers
Summary
Study in 249 patients with a range of advanced solid tumours (breast, NSCLC, SCLC, head and neck SCC, or gastro-oesophageal adenocarcinoma) that had relapsed or was refractory to chemotherapy given oral alisertib in 21-day cycles noted partial responses in 9 to 21% of patients.
UKMi comment
The aurora kinases (A, B, and C) have a key role in mitosis. Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. This study recorded clinical activity exceeding the prespecified criterion for further research in the breast cancer and small-cell lung cancer cohorts. The data also indicate that single-agent alisertib has a generally manageable toxicity profile at the recommended phase II dose. The researchers suggest these findings warrant future studies of alisertib as a single agent or in combination.
Related links: